Data completeness
1/8 — Limited
TEGOPEN (cloxacillin sodium) by Bristol Myers Squibb is action: cloxacillin benzathine is bactericidal in action against susceptible organisms during the stage of active multiplication.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEGOPEN (cloxacillin sodium) is an oral penicillinase-resistant penicillin antibiotic in solution form, developed by Bristol Myers Squibb. It is bactericidal against gram-positive organisms including penicillin G-resistant Staphylococcus aureus and Streptococcus agalactiae, acting by inhibiting bacterial cell wall biosynthesis. The product is currently in pre-launch stage.
Pre-Launch
Pre-launch stage suggests active commercial infrastructure building with early-stage team development and market preparation activities underway.
Mechanism of Action
ACTION: Cloxacillin benzathine is bactericidal in action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. It is active against gram-positive organisms associated with mastitis such as Staphylococcus…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TEGOPEN at pre-launch stage offers exposure to full product lifecycle launch planning, market access strategy, and commercial infrastructure development within Bristol Myers Squibb's antibiotic portfolio. Career growth potential depends on successful regulatory approval and subsequent market uptake in the competitive penicillinase-resistant penicillin segment.
Brand Manager
Worked on TEGOPEN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.